In terms of twelve month growth in earnings before interest and taxes, Venus Concept Inc is reporting a growth rate of 154.09%; that's higher than 91.56% of US stocks.
Revenue growth over the past 12 months for Venus Concept Inc comes in at 725.36%, a number that bests 98.9% of the US stocks we're tracking.
Venus Concept Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -86.42%, greater than the shareholder yield of just 4.32% of stocks in our set.
Stocks that are quantitatively similar to VERO, based on their financial statements, market capitalization, and price volatility, are FARM, PFMT, SUNW, MNTX, and NPO.
Venus Concept Inc. (formerly Restoration Robotics, Inc.), a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. It offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. The company was founded in 2002 and is based in San Jose, California.
The Non-Invasive Fat Reduction market report by Reports and Data provides an extensive overview of the vital elements of the Non-Invasive Fat Reduction market and factors such as the drivers, restraints, latest trends, supervisory scenario, competitive landscape, technological advancements, and
Venus Concept, Inc. (VERO) Q2 2020 Earnings Conference Call August 13, 2020, 17:00 ET Company Participants Domenic Serafino - CEO & Director Domenic Della Penna - CFO Chad Zaring - Chief Commercial Officer Conference Call Participants Suraj Kalia - Oppenheimer Anthony Vendetti - Maxim Group Marie Thibault - BTIG Presentation...
Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced that it has received FDA 510(k) clearance to market and sell Venus Viva MD. Venus Viva MD is a non-invasive device intended to be used by aesthetic-related physicians or dermatologists. It expands the Company’s skin rejuvenation offerings beyond the Venus Viva™ and Venus Versa™ which were introduced to the medical aesthetics market in 2015 and 2016, respectively.